← Back to Search

Bcl-2 Inhibitor

Venetoclax + Vincristine for Acute Lymphoblastic Leukemia

Phase 1 & 2
Recruiting
Led By Neil Palmisiano
Research Sponsored by ECOG-ACRIN Cancer Research Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adequate liver function with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than 3 X upper limit of normal and total bilirubin less than 2 mg/dL within 7 days prior to first dose of study agent
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Must not have
History of any lymphoproliferative disorder
Patients with poorly controlled human immunodeficiency virus (HIV), or CD4 < 400
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing the effects of venetoclax and vincristine liposomal on patients with T-cell or B-cell acute lymphoblastic leukemia.

Who is the study for?
This trial is for adults with T-cell or B-cell acute lymphoblastic leukemia that has returned or isn't responding to treatment. Participants must not be pregnant, should use effective contraception, and have no severe active infections like poorly controlled HIV. They shouldn't have other serious medical conditions that could affect participation, nor a history of certain cancers unless cured over 5 years ago. Recent chemotherapy recipients and those with high-grade peripheral neuropathy are excluded.
What is being tested?
The study is testing the combination of venetoclax, which blocks enzymes cancer cells need to grow, and vincristine liposomal, a chemotherapy drug that kills or stops cancer cells from dividing. The goal is to find the best dose of venetoclax and see if this combo works better for relapsed or refractory acute lymphoblastic leukemia.
What are the potential side effects?
Potential side effects include risks typical of chemotherapy such as nausea, hair loss, fatigue, increased risk of infection due to low blood cell counts; plus specific ones related to venetoclax like diarrhea and potential liver issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My liver tests are within normal limits.
Select...
I am able to care for myself and perform daily activities.
Select...
I do not have severe heart issues like advanced heart failure or uncontrolled chest pain.
Select...
My kidney function is good, with a creatinine clearance of at least 50 mL/min.
Select...
My cancer has not spread to my brain or testicles.
Select...
I do not have Burkitt's lymphoma/leukemia.
Select...
I am not pregnant or breast-feeding.
Select...
My leukemia has returned or didn't respond to treatment, with more than 5% cancer cells in my bone marrow.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a history of disorders related to lymphocyte proliferation.
Select...
My HIV is not well-controlled, or my CD4 count is below 400.
Select...
I have a history of cancer.
Select...
I have severe nerve damage in my hands or feet.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Complete remission (CR) + complete remission incomplete (CRi) rate (Phase II)
Incidence of toxicities (Phase I)
Secondary study objectives
Change in intracellular BCL-2 expression
Overall survival (OS)
Progression free survival (PFS)
+1 more
Other study objectives
BH3 profile
Expression of BCL-2
Genetic signature
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (venetoclax, vincristine liposomal)Experimental Treatment3 Interventions
Patients receive venetoclax PO QD on days 1-42 of course 1 and days 43-70 of course 2. Patients also receive vincristine liposomal IV weekly for 4 weeks starting on day 14 of course 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Venetoclax
2019
Completed Phase 3
~2200

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH
13,842 Previous Clinical Trials
41,002,926 Total Patients Enrolled
ECOG-ACRIN Cancer Research GroupLead Sponsor
119 Previous Clinical Trials
178,973 Total Patients Enrolled
Neil PalmisianoPrincipal InvestigatorECOG-ACRIN Cancer Research Group

Media Library

Venetoclax (Bcl-2 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03504644 — Phase 1 & 2
Acute Lymphoblastic Leukemia Research Study Groups: Treatment (venetoclax, vincristine liposomal)
Acute Lymphoblastic Leukemia Clinical Trial 2023: Venetoclax Highlights & Side Effects. Trial Name: NCT03504644 — Phase 1 & 2
Venetoclax (Bcl-2 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03504644 — Phase 1 & 2
~30 spots leftby Dec 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top